Filing Flows › Biogen (BIIB) › Free cash flow
Biogen (BIIB) free cash flow by quarter
Biogen's free cash flow was $600M in Q3 2026 (third quarter 2026), +47% from Q2 2026. Over the last 7 quarters it ranged from $134M (Q2 2025) to $1.2B (Q3 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $600M | +47% | -51% |
| Q2 2026 | $408M | -31% | +204% |
| Q1 2026 | $594M | +27% | +167% |
| Q4 2025 | $468M | -62% | — |
| Q3 2025 | $1.2B | +813% | — |
| Q2 2025 | $134M | -40% | — |
| Q1 2025 | $222M | — | — |
Q3 2026 at a glance
Biogen, Q3 2026: revenue $2.8B (+11% year over year), operating margin -0.3%, net loss $20.6M, operating cash flow $641M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biogen's free cash flow?
Biogen's free cash flow was $600M in Q3 2026 (third quarter 2026), +47% from Q2 2026.
How has Biogen's free cash flow changed?
Over the last 7 quarters it ranged from $134M (Q2 2025) to $1.2B (Q3 2025).